<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111040</article-id><article-id pub-id-type="publisher-id">ACM-40008</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_29582866.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  94例中草药相关肝损伤患者的临床及预后分析
  Clinical and Prognostic Analysis of 94 Patients with Herb-Induced Liver Injury
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贺</surname><given-names>然</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>希双</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>275</fpage><lpage>281</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：通过分析94例中草药相关肝损伤(HILI)患者的一般特征、临床表现、实验室指标、肝组织病理及影响预后的因素，更好地指导相关中草药的合理用药，降低药物性肝损伤的发病率。方法：回顾性分析2018年1月至2019年12月就诊于某医院诊断为HILI患者的一般资料、中草药用药史、基础疾病、临床表现、实验室指标、肝组织病理、治疗及影响预后的因素。结果：本研究中94例HILI患者年龄分布为14~80岁，其中女性60例，男性34例，以41~60年龄段居多。HILI患者以黄疸及消化道症状最常见，主要为尿黄(42例，44.7%)、黄疸(34例，36.2%)、恶心(27例，28.7%)、腹痛(20例，21.3%)、乏力(11例，11.7%)、陶土样便(5例，5.3%)，少数出现发热(7例，7.4%)、皮疹(2例，2.1%)等全身性反应。HILI患者临床分型以肝细胞损伤型(77例，81.9%)最常见，其次是胆汁淤积型(11例，11.7%)、混合型(6例，6.4%)。94例HILI患者经治疗后85例(90.4%)好转出院，8例(8.5%)未愈出院，1例(1.1%)进展为失代偿期肝硬化。经统计分析年龄、临床分型、INR、Alb对预后有统计学意义，而性别、吸烟史、BMI、ALT、AST、TBIL、DBIL、ALP、GGT对预后无统计学意义，多因素分析Alb可能是预后的独立预测指标。结论：中草药相关肝损伤发病率呈逐年上升趋势，引起肝损伤的中草药种类繁多，以何首乌、土三七、雷公藤较为常见。HILI多发生于中老年女性，其临床表现无特异性，以黄疸、尿黄为主，HILI临床分型以肝细胞损伤型为主，HILI患者的肝组织病理无明显特异性，多数伴有嗜酸性粒细胞浸润、中央静脉周围肝细胞点灶状坏死及肝细胞凋亡小体。HILI患者大多数预后较好，极少数预后不良进展为肝衰竭或失代偿期肝硬化。
    Objective: To analyze the general characteristics, clinical manifestations, laboratory indicators, liver histopathology and prognostic factors of 94 patients with herb-induced liver injury, so as to guide the rational use of relevant Chinese herbal medicine and reduce the incidence of drug-induced liver injury. Methods: The general data of HILI patients diagnosed at the Affiliated Hospital of Qingdao University from January 2018 to December 2019 were analyzed retrospectively, including clinical manifestations, basic diseases, laboratory indicators, liver histopathology and prognostic factors. Results: In this study, the age distribution of 94 HILI patients was 14~80 years old, including 60 females and 34 males, mostly in the age group of 41~60. Symptoms of jaundice and digestive symptoms were most common in HILI patients, mainly including urine yellow (42 cases, 44.7%), jaundice (34 cases, 36.2%), nausea (27 cases, 28.7%), abdominal pain (20 cases, 21.3%), fatigue (11 cases, 11.7%), grey stools (5 cases, 5.3%), and a few systemic reactions such as fever (7 cases, 7.4%) and rash (2 cases, 2.1%). The most common clinical type of HILI patients was hepatocellular (77 cases, 81.9%), followed by cholestatic (11 cases, 11.7%) and mixed type (6 cases, 6.4%). Of the 94 HILI patients, 85 (90.4%) were discharged from hospital after treatment, 8 (8.5%) were discharged from hospital without recovery, and 1 (1.1%) developed decompensated cirrhosis. After statistical analysis, age, clinical types, Alb and INR had statistical significance for prognosis, while gender, smoking history, BMI, ALT, AST, TBIL, DBIL, ALP and GGT had no statistical significance for prognosis. Multivariate analysis of Alb may be an independent predictor of prognosis. Conclusion: The incidence of herb-induced liver injury is on the rise year by year. There are many kinds of Chinese herbal medicines causing liver injury, such as Polygonum multiflorum, Tunopanax notoginseng and Tripterygium wilfordii. HILI mostly occurs in middle-aged and elderly women, and its clinical manifestations are non-specific, mainly jaundice and urinary yellow. The most common clinical type of HILI is hepatocellular. The liver histopathology of HILI patients has no obvious specificity, most of which are accompanied by eosinophil infiltration, focal hepatocyte necrosis around the central vein, and hepatocyte apoptosis bodies. Most patients with HILI have a good prognosis, with a small minority progressing to hepatic failure or decompensated cirrhosis. 
  
 
</p></abstract><kwd-group><kwd>中草药相关肝损伤，临床特点，肝组织病理，治疗，预后, Herb-Induced Liver Injury</kwd><kwd> Clinical Characteristics</kwd><kwd> Liver Histopathology</kwd><kwd> Treatment</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：通过分析94例中草药相关肝损伤(HILI)患者的一般特征、临床表现、实验室指标、肝组织病理及影响预后的因素，更好地指导相关中草药的合理用药，降低药物性肝损伤的发病率。方法：回顾性分析2018年1月至2019年12月就诊于某医院诊断为HILI患者的一般资料、中草药用药史、基础疾病、临床表现、实验室指标、肝组织病理、治疗及影响预后的因素。结果：本研究中94例HILI患者年龄分布为14~80岁，其中女性60例，男性34例，以41~60年龄段居多。HILI患者以黄疸及消化道症状最常见，主要为尿黄(42例，44.7%)、黄疸(34例，36.2%)、恶心(27例，28.7%)、腹痛(20例，21.3%)、乏力(11例，11.7%)、陶土样便(5例，5.3%)，少数出现发热(7例，7.4%)、皮疹(2例，2.1%)等全身性反应。HILI患者临床分型以肝细胞损伤型(77例，81.9%)最常见，其次是胆汁淤积型(11例，11.7%)、混合型(6例，6.4%)。94例HILI患者经治疗后85例(90.4%)好转出院，8例(8.5%)未愈出院，1例(1.1%)进展为失代偿期肝硬化。经统计分析年龄、临床分型、INR、Alb对预后有统计学意义，而性别、吸烟史、BMI、ALT、AST、TBIL、DBIL、ALP、GGT对预后无统计学意义，多因素分析Alb可能是预后的独立预测指标。结论：中草药相关肝损伤发病率呈逐年上升趋势，引起肝损伤的中草药种类繁多，以何首乌、土三七、雷公藤较为常见。HILI多发生于中老年女性，其临床表现无特异性，以黄疸、尿黄为主，HILI临床分型以肝细胞损伤型为主，HILI患者的肝组织病理无明显特异性，多数伴有嗜酸性粒细胞浸润、中央静脉周围肝细胞点灶状坏死及肝细胞凋亡小体。HILI患者大多数预后较好，极少数预后不良进展为肝衰竭或失代偿期肝硬化。</p></sec><sec id="s2"><title>关键词</title><p>中草药相关肝损伤，临床特点，肝组织病理，治疗，预后</p></sec><sec id="s3"><title>Clinical and Prognostic Analysis of 94 Patients with Herb-Induced Liver Injury</title><p>Ran He, Xishuang Liu<sup>*</sup></p><p>Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/40-1571874x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/40-1571874x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the general characteristics, clinical manifestations, laboratory indicators, liver histopathology and prognostic factors of 94 patients with herb-induced liver injury, so as to guide the rational use of relevant Chinese herbal medicine and reduce the incidence of drug-induced liver injury. Methods: The general data of HILI patients diagnosed at the Affiliated Hospital of Qingdao University from January 2018 to December 2019 were analyzed retrospectively, including clinical manifestations, basic diseases, laboratory indicators, liver histopathology and prognostic factors. Results: In this study, the age distribution of 94 HILI patients was 14~80 years old, including 60 females and 34 males, mostly in the age group of 41~60. Symptoms of jaundice and digestive symptoms were most common in HILI patients, mainly including urine yellow (42 cases, 44.7%), jaundice (34 cases, 36.2%), nausea (27 cases, 28.7%), abdominal pain (20 cases, 21.3%), fatigue (11 cases, 11.7%), grey stools (5 cases, 5.3%), and a few systemic reactions such as fever (7 cases, 7.4%) and rash (2 cases, 2.1%). The most common clinical type of HILI patients was hepatocellular (77 cases, 81.9%), followed by cholestatic (11 cases, 11.7%) and mixed type (6 cases, 6.4%). Of the 94 HILI patients, 85 (90.4%) were discharged from hospital after treatment, 8 (8.5%) were discharged from hospital without recovery, and 1 (1.1%) developed decompensated cirrhosis. After statistical analysis, age, clinical types, Alb and INR had statistical significance for prognosis, while gender, smoking history, BMI, ALT, AST, TBIL, DBIL, ALP and GGT had no statistical significance for prognosis. Multivariate analysis of Alb may be an independent predictor of prognosis. Conclusion: The incidence of herb-induced liver injury is on the rise year by year. There are many kinds of Chinese herbal medicines causing liver injury, such as Polygonum multiflorum, Tunopanax notoginseng and Tripterygium wilfordii. HILI mostly occurs in middle-aged and elderly women, and its clinical manifestations are non-specific, mainly jaundice and urinary yellow. The most common clinical type of HILI is hepatocellular. The liver histopathology of HILI patients has no obvious specificity, most of which are accompanied by eosinophil infiltration, focal hepatocyte necrosis around the central vein, and hepatocyte apoptosis bodies. Most patients with HILI have a good prognosis, with a small minority progressing to hepatic failure or decompensated cirrhosis.</p><p>Keywords:Herb-Induced Liver Injury, Clinical Characteristics, Liver Histopathology, Treatment, Prognosis</p><disp-formula id="hanspub.40008-formula22"><graphic xlink:href="//html.hanspub.org/file/40-1571874x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/40-1571874x8_hanspub.png" /> <img src="//html.hanspub.org/file/40-1571874x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>中草药相关肝损伤(Herb-induced liver injury, HILI)是指由中药、天然药物及其相关制剂引发的肝损伤 [<xref ref-type="bibr" rid="hanspub.40008-ref1">1</xref>]。在西方国家NSAIDS是药物性肝损伤的主要病因 [<xref ref-type="bibr" rid="hanspub.40008-ref2">2</xref>]，其有关中草药的研究相对滞后，而我国由于中草药的广泛应用，中草药相关肝损伤的发病率呈逐年上升趋势，国内许多研究对常见中草药致肝损伤的发病机制作出了阐述。影响HILI的发生一方面是中草药的炮制方法、剂型、用量、疗程、不合理配伍等，另一方面是机体差异性因素，如性别、年龄、体质、基础疾病等 [<xref ref-type="bibr" rid="hanspub.40008-ref3">3</xref>]。本研究通过收集94例中草药相关肝损伤患者的年龄、性别、体质指数、基础疾病、吸烟史等一般资料及临床特点，回顾性分析影响预后的因素，对指导中草药安全合理化用药及减少药物性肝损伤有重要意义。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 资料来源</title><p>本研究资料来源于2018年1月至2019年12月就诊于某医院诊断为HILI的94例患者。查阅病历系统收集并记录患者的年龄、性别、体质指数、中草药用药史、吸烟史、基础疾病、临床表现、实验室指标、肝组织病理、治疗用药及预后等信息。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>依据2016年中草药相关肝损伤指南确定诊断标准：肝功能异常前有中草药及其相关制剂应用史且1) ALT ≥ 5 ULN；2) ALP ≥ 2 ULN，特别是伴有5′-核苷酸酶或GGT升高且排除骨病引起的ALP升高；3) ALT ≥ 3 ULN且TBil ≥ 2 ULN，参照RUCAM评分 [<xref ref-type="bibr" rid="hanspub.40008-ref1">1</xref>]，肝损伤与药物的关系分为“高度相关”(&gt;8分)、“很可能相关”(6~8分)、“可能相关”(3~5分)、“可能无关”(1~2分)、“排除”(≤0分)。本研究的纳入标准为符合上述诊断标准、发病前中草药及其制剂为唯一用药且RUCAM评分 ≥ 6分的患者。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>HILI诊断仍属于排除性诊断，需要排除病毒性肝炎、非酒精性脂肪性肝病、酒精性肝病、自身免疫性肝病、遗传代谢性肝病及胆道和血管疾病等导致的肝损伤。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS22.0统计软件进行分析，计量资料以“ x &#175; &#177; s ”表示，符合正态分布者两组间均数比较采用独立样本t检验，非符合正态分布者采用秩和检验；计数资料采用c2检验。本研究首先单因素分析年龄、性别、体质指数、吸烟史、临床分型、肝生化指标与预后的关系，对有统计学意义的指标进行多因素Logistic回归分析，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. HILI患者的性别及年龄分布</title><p>本研究94例HILI患者年龄分布为14~80岁，其中女性60例，男性34例，发病年龄主要集中于41~60岁，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Age and sex distribution of HILI patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >年龄段</th><th align="center" valign="middle" >男性</th><th align="center" valign="middle" >女性</th><th align="center" valign="middle" >合计</th></tr></thead><tr><td align="center" valign="middle" >0~20</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >21~40</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >41~60</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >47</td></tr><tr><td align="center" valign="middle" >61~80</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >94</td></tr></tbody></table></table-wrap><p>表1. HILI患者的年龄及性别分布</p></sec><sec id="s7_2"><title>3.2. 体质指数</title><p>本研究94例患者体质指数平均水平为23.98 &#177; 0.7，BMI &lt; 18.5 (消瘦)：0例，18.5 ≤ BMI &lt; 24 (正常)：48例，24 ≤ BMI &lt; 28 (超重)：39例，BMI ≥ 28 (肥胖)：7例，经单因素分析BMI对预后无统计学意义(P = 0.491)。</p></sec><sec id="s7_3"><title>3.3. 基础疾病</title><p>本研究患者合并的基础疾病排前3位的是慢性胃炎、腰椎间盘突出症、糖尿病。</p></sec><sec id="s7_4"><title>3.4. 吸烟史</title><p>本研究有吸烟史的患者为8例，无吸烟史的患者86例。吸烟史对预后无统计学意义(P = 0.179)。</p></sec><sec id="s7_5"><title>3.5. 临床表现</title><p>HILI患者的临床表现无明显特异性，本研究94例患者起病以尿黄、黄疸及消化道症状较为多见，其中尿黄(42例，44.7%)、黄疸(34例，36.2%)、恶心(27例，28.7%)、腹痛(20例，21.3%)、乏力(11例，11.7%)、陶土样便(5例，5.3%)，少数出现发热(7例，7.4%)、皮疹(2例，2.1%)等全身性反应。</p></sec><sec id="s7_6"><title>3.6. 临床分型</title><p>本研究基于受损靶细胞类型进行分类，94例HILI患者中肝细胞损伤型77例(81.9%)，胆汁淤积型11例(11.7%)以及混合型6例(6.4%)。不同临床分型对预后有统计学意义(P = 0.019)。</p></sec><sec id="s7_7"><title>3.7. 肝组织病理</title><p>本研究94例HILI患者中有15例进行了肝穿刺活检，15例病理均可见汇管区淋巴细胞及嗜酸性粒细胞浸润、中央静脉周围肝细胞点灶状坏死，其中3例病理可见肝细胞凋亡小体。</p></sec><sec id="s7_8"><title>3.8. 治疗</title><p>本研究94例患者均在发现肝生化指标异常后停用可疑药物，并应用异甘草酸、还原型谷胱甘肽作为基础药物治疗，对于部分胃肠道反应较重的患者予以静脉滴注PPI治疗，其中2例存在自身免疫样反应的患者停药后转氨酶及总胆红素水平居高不下，经糖皮质激素治疗转氨酶下降&gt;50%后出院，1例因肝衰竭行人工肝治疗，1例因最终发展为失代偿期肝硬化行肝移植手术。</p></sec><sec id="s7_9"><title>3.9. 预后</title><p>本研究94例HILI患者中85例(90.4%)好转出院，8例(8.5%)未愈出院，1例转氨酶水平居高不下后期进展为失代偿期肝硬化最终行肝移植手术，无死亡患者。将94例患者根据预后(好转和治愈为预后良好，未愈及死亡为预后不良)分为预后良好组(85例)与预后不良组(9例)。经单因素分析患者的年龄、临床分型、INR、ALb对预后有统计学意义(P &lt; 0.05)；性别、体质指数、吸烟史、ALT、AST、TBIL、DBIL、ALP、GGT对预后无统计学意义(P &gt; 0.05)。经多因素分析Alb可能为预后的独立预测因素(P = 0.005)，具体见表2~5。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>近年来由于中草药的广泛应用，中草药相关肝损伤的发病率呈逐年上升趋势。据统计HILI占所有药物性肝损伤(Drug-induced liver injury, DILI)的16.17%~25.37% [<xref ref-type="bibr" rid="hanspub.40008-ref4">4</xref>]。通过多项研究分析中草药相关肝损伤的发生一方面可能受中草药的炮制过程、剂量、剂型、配伍不合理等因素影响，另一方面机体差异性因素如年龄、性别、体质指数、基础疾病等也与中草药相关肝损伤的发生有关 [<xref ref-type="bibr" rid="hanspub.40008-ref3">3</xref>]。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Univariate analysis of prognostic factor</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >预后良好</th><th align="center" valign="middle" >预后不良</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >50.0 &#177; 14.0</td><td align="center" valign="middle" >61.1 &#177; 13.6</td><td align="center" valign="middle" >0.025</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >23.9 &#177; 2.8</td><td align="center" valign="middle" >24.6 &#177; 3.5</td><td align="center" valign="middle" >0.491</td></tr><tr><td align="center" valign="middle" >ALT</td><td align="center" valign="middle" >940.5 &#177; 762.1</td><td align="center" valign="middle" >555.7 &#177; 750.7</td><td align="center" valign="middle" >0.153</td></tr><tr><td align="center" valign="middle" >AST</td><td align="center" valign="middle" >607.9 &#177; 623.6</td><td align="center" valign="middle" >342.8 &#177; 304.3</td><td align="center" valign="middle" >0.213</td></tr><tr><td align="center" valign="middle" >TBIL</td><td align="center" valign="middle" >101.9 &#177; 106.2</td><td align="center" valign="middle" >163.8 &#177; 156.2</td><td align="center" valign="middle" >0.276</td></tr><tr><td align="center" valign="middle" >DBIL</td><td align="center" valign="middle" >66.7 &#177; 78.0</td><td align="center" valign="middle" >112.5 &#177; 112.2</td><td align="center" valign="middle" >0.263</td></tr><tr><td align="center" valign="middle" >ALP</td><td align="center" valign="middle" >146.4 &#177; 82.4</td><td align="center" valign="middle" >243.7 &#177; 168.0</td><td align="center" valign="middle" >0.123</td></tr><tr><td align="center" valign="middle" >GGT</td><td align="center" valign="middle" >177.9 &#177; 154.6</td><td align="center" valign="middle" >184.0 &#177; 171.0</td><td align="center" valign="middle" >0.912</td></tr><tr><td align="center" valign="middle" >Alb</td><td align="center" valign="middle" >38.5 &#177; 4.5</td><td align="center" valign="middle" >32.2 &#177; 6.3</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >INR</td><td align="center" valign="middle" >1.0 &#177; 0.2</td><td align="center" valign="middle" >1.8 &#177; 1.3</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表2. 影响预后的单因素分析</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Influence of gender on prognosis of HILI patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >性别</th><th align="center" valign="middle" >预后良好组</th><th align="center" valign="middle" >预后不良组</th><th align="center" valign="middle" >n</th></tr></thead><tr><td align="center" valign="middle" >男性</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >34</td></tr><tr><td align="center" valign="middle" >女性</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >60</td></tr><tr><td align="center" valign="middle" >c2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.587</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.858</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 性别对HILI患者预后的影响</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Influence of different clinical types on prognosis of HILI patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床分型</th><th align="center" valign="middle" >预后良好组</th><th align="center" valign="middle" >预后不良组</th><th align="center" valign="middle" >n</th></tr></thead><tr><td align="center" valign="middle" >肝细胞损伤型</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >77</td></tr><tr><td align="center" valign="middle" >胆汁淤积型</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >c2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.019</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 不同临床分型对HILI患者预后的影响</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Influence of smoking history on prognosis of HILI patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >吸烟史</th><th align="center" valign="middle" >预后良好</th><th align="center" valign="middle" >预后不良</th><th align="center" valign="middle" >n</th></tr></thead><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >86</td></tr><tr><td align="center" valign="middle" >c2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.121</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.179</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表5. 吸烟史对HILI患者预后的影响</p><p>查阅相关文献发现引起肝损伤的中草药种类较多，而当作为治疗用药时人们往往多种中草药联用，本研究涉及较多的中草药有何首乌、土三七、雷公藤、千里光、大黄等以及中药复方制剂润燥止痒胶囊，主要用于治疗白发、白癜风、痤疮、类风湿关节炎、腰腿痛、慢性胃炎等疾病。不同的中草药致肝损伤的机制也各有不同。据相关研究雷公藤是通过其主要成分雷公藤甲素促进肝细胞凋亡从而对肝脏产生强烈毒性及损伤 [<xref ref-type="bibr" rid="hanspub.40008-ref3">3</xref>]；土三七经研究可通过破坏细胞有丝分裂引起肝小静脉炎症从而致管腔狭窄甚至闭塞，即肝小静脉闭塞症，后期可进展为肝硬化 [<xref ref-type="bibr" rid="hanspub.40008-ref5">5</xref>]；据刘传梦等人的研究，何首乌致肝损伤的机制可能是其含有的没食子酸加速细胞凋亡以及其某种成分对肝脏胆汁酸的合成、转运、排泄产生影响从而致胆汁淤积 [<xref ref-type="bibr" rid="hanspub.40008-ref6">6</xref>]。</p><p>HILI在任何年龄段均可发病，本研究患者年龄集中于41~60岁，以中青年女性多见，这一方面是由于与男性相比女性更易于因自我保健的需求去应用药物，另一方面可能是由于该年龄段女性的雌孕激素水平变化影响肝酶细胞色素CYP450活性、降低药物清除速度从而造成肝损伤 [<xref ref-type="bibr" rid="hanspub.40008-ref7">7</xref>]，但女性患者的肝损伤严重程度及死亡率并不高于男性 [<xref ref-type="bibr" rid="hanspub.40008-ref8">8</xref>]。本研究把体质指数也纳为观察指标，发现94 例HILI 患者中超重及肥胖患者的比例为48.9%，但经统计分析其对预后无统计学意义，这与相关研究结果也是一致的。94例HILI患者合并的基础疾病排前三位的为慢性胃炎、腰椎间盘突出症、糖尿病，根据于乐成等人的报道 [<xref ref-type="bibr" rid="hanspub.40008-ref9">9</xref>] 了解到糖尿病是某些药物引起肝损伤的易感因素，也有研究提示糖尿病与药物性肝损伤的严重程度独立相关。HILI的临床表现无明显特异性，44.7%的患者出现尿黄，36.2%患者以黄疸为首发症状，部分患者无临床症状而是于查体时发现肝生化指标异常就诊，少数患者出现发热、皮疹等全身性症状。正是由于这部分无症状患者的存在使得药物性肝损伤的检出率较低，也因此难以收集足够的案例致使相关研究滞后。本研究基于受损靶细胞类型进行临床分型，94例患者以肝细胞损伤型最为常见，其次是胆汁淤积型、混合型，这也与相关研究具有一致性。</p><p>当进行药物性肝损伤诊断时，通过患者的临床特点及肝生化指标无法确诊时可行肝穿刺活检。药物性肝损伤病理主要表现为肝细胞损伤、炎细胞浸润、纤维组织增生、胆管损伤和血管病变等非特异性改变 [<xref ref-type="bibr" rid="hanspub.40008-ref9">9</xref>]。中草药相关肝损伤的病理表现为汇管区明显纤维增生、界面炎，与西药引起的肝损伤病理难以区别。但是肝组织明显嗜酸粒细胞浸润及中央静脉周围肝细胞点灶状坏死等病理特点可作为药物性肝损伤区别于其他病因肝损伤的重要依据 [<xref ref-type="bibr" rid="hanspub.40008-ref4">4</xref>]。</p><p>中草药相关肝损伤发生后大多数患者需立即停用可疑药物，尽早行药物治疗。常用药物有抗自由基损伤药如N-乙酰半胱氨酸，抗炎保肝药如甘草酸制剂及水飞蓟素，促进胆红素和胆汁酸代谢药物如S-腺苷蛋氨酸及熊去氧胆酸 [<xref ref-type="bibr" rid="hanspub.40008-ref9">9</xref>]。异甘草酸镁对于ALT升高明显的急性肝细胞损伤疗效较好，熊去氧胆酸对胆汁淤积型患者疗效较好，对于部分炎症反应较重、停药后肝生化指标居高不下或是存在自身免疫征象的患者可酌情应用糖皮质激素，但激素的使用疗效目前尚无循证医学证据支持，故需严格掌握适应证。本研究中2例存在自身免疫样反应的患者经常用药物治疗后疗效不佳，加用激素1周后临床症状好转、转氨酶及胆红素下降&gt;50%。如果肝损伤患者经常规治疗后病情进一步加重可行人工肝支持疗法，若发展至肝衰竭甚至出现失代偿期肝硬化可考虑肝移植手术。</p><p>HILI整体预后较好，极少数患者发展为肝衰竭甚至失代偿期肝硬化需行人工肝治疗或肝移植手术。据一项多中心研究在中国43%的急性肝衰竭是由药物引起的 [<xref ref-type="bibr" rid="hanspub.40008-ref10">10</xref>]，本研究中2例患者进展为肝衰竭，其中1例进行了人工肝治疗。本研究通过统计分析发现患者的年龄、临床分型、INR、Alb对预后有统计学意义，性别、体质指数、吸烟史、ALT、AST、TBIL、DBIL、ALP、GGT对预后无统计学意义，Alb可能为预后的独立危险因素，不同临床分型非预后的独立危险因素。</p><p>中草药在我国历史悠久且有着不容小觑的地位。受传统文化的影响，中药无毒、比西药安全的观点在许多国民心中根深蒂固，尽管某些疾病西药的疗效更佳，人们却往往更热衷于中药治疗，这种盲目认知要求我们更多的去开展中草药致肝损伤的相关研究，通过关注引起肝损伤的可疑中草药及其带来的不良反应，进一步加深对中草药的认识，为中草药的安全合理化应用提供更多地参考依据。</p></sec><sec id="s9"><title>文章引用</title><p>贺 然,刘希双. 94例中草药相关肝损伤患者的临床及预后分析Clinical and Prognostic Analysis of 94 Patients with Herb-Induced Liver Injury[J]. 临床医学进展, 2021, 11(01): 275-281. https://doi.org/10.12677/ACM.2021.111040</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40008-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">肖小河, 等. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32(5): 835-843.</mixed-citation></ref><ref id="hanspub.40008-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., et al. (2013) Epidemiology of Drug-Induced Liver Injury in China: A Systematic Analysis of the Chinese Literature Including 21,789 Patients. European Journal of Gastroenterology &amp; Hepatology, 25, 825-829.  
&lt;br&gt;https://doi.org/10.1097/MEG.0b013e32835f6889</mixed-citation></ref><ref id="hanspub.40008-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">吴豪, 等. 潜在肝毒性中药的成分研究进展[J]. 中国中药杂志, 2016, 41(17): 3209-3217.</mixed-citation></ref><ref id="hanspub.40008-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">郑俊福, 刘晖, 丁惠国. 中草药致药物性肝损害的临床特点与病理分析[J]. 中华临床医师杂志(电子版), 2011, 5(3): 720-725.</mixed-citation></ref><ref id="hanspub.40008-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">石振东. 中草药相关肝损伤的发病机制、临床特点和防治策略[J]. 中国现代医药杂志, 2017. 19(10): 101-104.</mixed-citation></ref><ref id="hanspub.40008-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">刘传梦, 等. 中草药相关肝损伤机制研究进展[J]. 中华中医药学刊, 2020, 38(6): 177-181.</mixed-citation></ref><ref id="hanspub.40008-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Cho, J., et al. (2013) Sex Bias in Experimental Immune-Mediated, Drug-Induced Liver Injury in BALB/c Mice: Suggested Roles for Tregs, Estrogen, and IL-6. PloS One, 8, e61186. &lt;br&gt;https://doi.org/10.1371/journal.pone.0061186</mixed-citation></ref><ref id="hanspub.40008-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, C., et al. (2020) Characteristics of Drug-Induced Liver Injury in Northeast China: Disease Spectrum and Drug Types. Digestive Diseases and Sciences, 65, 3360-3368. &lt;br&gt;https://doi.org/10.1007/s10620-019-06030-6</mixed-citation></ref><ref id="hanspub.40008-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11: 1752-1769.</mixed-citation></ref><ref id="hanspub.40008-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, P., et al. (2013) Causes and Outcomes of Acute Liver Failure in China. PloS One, 8, e80991.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0080991</mixed-citation></ref></ref-list></back></article>